Kuur Therapeutics Cell Therapies

Kuur Therapeutics (formerly known as Cell Medica) is a clinical-stage biopharmaceutical company that specializes in developing 'off-the-shelf' engineered CAR-NKT cell therapies for the treatment of solid and hematological tumors. The brand originated in London, UK, but relocated its core headquarters to Houston, Texas, to leverage the medical innovation ecosystem in the United States.

In May 2021, the company underwent a significant ownership change when it was acquired by Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for cancer. This acquisition was aimed at integrating Kuur's NKT cell platform with Athenex’s existing oncology pipeline. Today, the brand's intellectual property and clinical programs are managed under the umbrella of its parent company, primarily operating and manufacturing within the United States.